menu

contact
Italian Trulli

Tissue Selective
drug discovery

Bonito is a Boston-area biotech unlocking next generation targeted delivery. Using our small molecule and antibody discovery engines, we develop ligands that deliver payloads to any cell or tissue type. The core application is RNAi (siRNA, ASO) delivery to select tissue types with high precision and there are further applications in oncology and small molecule therapeutic discovery.

Contact us
Italian Trulli
Italian Trulli
Italian Trulli
Italian Trulli
Italian Trulli

Harnessing the power of AI to generate novel delivery molecules

Unlocking Next Generation Delivery Vehicles

Bonito is a Boston-area biotech unlocking next generation targeted delivery. Using our small molecule and antibody discovery engines, we develop ligands that deliver payloads to any cell or tissue type. The core application is RNAi (siRNA, ASO) delivery to select tissue types with high precision and there are further applications in oncology and small molecule therapeutic discovery.

Italian Trulli
Italian Trulli
Italian Trulli
Italian Trulli

experience & leadership

Bonito is led by an experienced team of entrepreneurs and innovative scientists with a track record of pioneering display technologies and oligonucleotide therapeutics.

Reach out

Our Leadership

Richard Wagner Ph.D.

Richard Wagner Ph.D.

CEO, Cofounder

Richard Wagner Ph.D.

Brant Binder

President, Cofounder

Richard Wagner Ph.D.

Steve Shamah, Ph.D.

CSO

Richard Wagner Ph.D.

Yun Ding, Ph.D.

SVP Head of Chemistry

Richard Wagner Ph.D.

Chris Kollmann

VP Selection Sciences

Richard Wagner Ph.D.

Jim Weterings, Ph.D.

VP Head of Oligo Discovery

Richard Wagner Ph.D.

Ribhu Nayar, Ph.D.

Sr. Dir. Head of Biology

Want to collaborate?

If you're interested in collaborating with Bonito we'd love to hear from you!

Contact us

Find Bonito on linkedin

Connect with Bonito on Linkedin for future news and company updates.

Our Linkedin
Italian Trulli

The future of targeted delivery

© Bonito Biosciences 2025